Home > Cardiology > HFA 2022 > DAPA-HF: Dapagliflozin safe and efficacious in frail patients

DAPA-HF: Dapagliflozin safe and efficacious in frail patients

Presented By
Dr Jawad Haider Butt, Copenhagen University Hospital, Denmark
Conference
HFA 2022
Trial
DAPA-HF
Dapagliflozin, added to guideline-recommended therapies, was associated with a reduction of major cardiovascular events and all-cause death in patients with heart failure and reduced ejection fractions (HFrEF) irrespective of frailty status. Furthermore, the drug was well tolerated regardless of frailty status. These results may aid physicians who are reluctant to prescribe medications to frail patients [1]. “HF and frailty often coexist,” said Dr Jawad Haider Butt (Copenhagen University Hospital, Denmark). “Since frail patients may experience more adverse drug reactions, physicians are often reluctant to introduce new therapies to frail patients.” The DAPA-HF trial (NCT03036124) randomised 4,744 patients with HF and an ejection fraction of ≤40% to placebo or dapagliflozin [2]. In this population, dapagliflozin added to guideline-recommended therapies reduc...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on